Novo Nordisk has released the full results of its landmark SOUL clinical trial, confirming that oral semaglutide not only helps manage blood sugar but also significantly reduces the risk of major ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound clinical impact for our patients who now have an oral option to improve ...